These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies. Darras V; Thienpont M; Stump DC; Collen D Thromb Haemost; 1986 Dec; 56(3):411-4. PubMed ID: 3105111 [TBL] [Abstract][Full Text] [Related]
3. The biphasic nature and temperature dependence of the activation of human plasminogen by urokinase. A simple urokinase assay based on this phenomenon. Ambrus CM; Bartfay-Szabo A; Mirand E; Ambrus JL Res Commun Chem Pathol Pharmacol; 1979 May; 24(2):339-47. PubMed ID: 461988 [TBL] [Abstract][Full Text] [Related]
4. [Immunosorption method of urokinase determination]. Isachenkov VA; Vakulina OP; Tomilin VA Vopr Med Khim; 1988; 34(6):133-6. PubMed ID: 3070932 [TBL] [Abstract][Full Text] [Related]
5. Simultaneous determination of free tissue-type and free urokinase-type plasminogen activators in biological fluids by a solid-phase immunoassay. Kuo BS; Bjornsson TD Anal Biochem; 1993 Feb; 209(1):70-8. PubMed ID: 8465964 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B. Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743 [TBL] [Abstract][Full Text] [Related]
7. A spectrophotometric assay for the determination of the catalytic efficiency of plasminogen activators using a slowly hydrolyzed plasmin substrate. Castro MJ; Kingston IB; Anderson S Anal Biochem; 1995 Apr; 226(2):225-31. PubMed ID: 7793622 [TBL] [Abstract][Full Text] [Related]
8. Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer. Koelbl H; Kirchheimer JC; Tatra G; Christ G; Binder BR Obstet Gynecol; 1988 Aug; 72(2):252-6. PubMed ID: 3134631 [TBL] [Abstract][Full Text] [Related]
11. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis. Collen D; Stassen JM; Blaber M; Winkler M; Verstraete M Thromb Haemost; 1984 Aug; 52(1):27-30. PubMed ID: 6541817 [TBL] [Abstract][Full Text] [Related]
13. [Experimental studies on the mode and amount of urokinase administration in thrombolytic therapy (author's transl)]. Matsuo O; Mihara H Rinsho Ketsueki; 1977 Sep; 18(9):1097-101. PubMed ID: 592505 [No Abstract] [Full Text] [Related]
14. Thrombolytic effects of tissue-type and urokinase-type plasminogen activators in rabbits with experimental pulmonary thromboembolization. Rahman F Fukuoka Igaku Zasshi; 1990 Sep; 81(9):303-12. PubMed ID: 2125971 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of fibrinolytic capacity in plasma during thrombolytic therapy with single (scu-PA) or two-chain urokinase type plasminogen activator (tcu-PA) by a combined assay system for urokinase type plasminogen activator antigen and function. Wojta J; Binder BR; Huber K; Hoover RL Thromb Haemost; 1989 Apr; 61(2):289-93. PubMed ID: 2501899 [TBL] [Abstract][Full Text] [Related]
16. Single-chain, urokinase-type plasminogen activator in a tumor model linked to metastatic potential. Kellen JA; Mirakian A; Wong A In Vivo; 1988; 2(2):155-7. PubMed ID: 2979833 [TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays. Camiolo SM; Greco WR Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257 [TBL] [Abstract][Full Text] [Related]
18. Expression and localization of the urokinase-type plasminogen activator receptor (uPAR) in the human placenta. Nishida Y; Hayashi Y; Imai Y; Itoh H Kobe J Med Sci; 1998 Feb; 44(1):31-43. PubMed ID: 9846056 [TBL] [Abstract][Full Text] [Related]
19. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase. Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163 [TBL] [Abstract][Full Text] [Related]
20. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B]. Wu XR; Wang Q; Shi SS; Lu MH; Guo WD Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]